Journal article

Publication year: 2024

Pages: 73-81

Journal: Transfusionsmedizin

Volume number: 14

Issue number: 02

ISSN: 2191-8805

eISSN: 2191-8813

DOI Link: https://doi.org/10.1055/a-2138-6082

Publisher: Georg Thieme Verlag

Abstract: 
The transport of maternal IgG antibodies into the fetal circulation provides the offspring with passive humoral immunity. The transplacental transport of IgG antibodies takes place in a complex process in which the neonatal receptor for the crystallizable fragment of IgG molecules (fragment cristallizable receptor neonatal, FcRn) is essentially involved. FcRn is ubiquitously expressed in the adult organism, regulates IgG and albumin homeostasis as well as innate and adaptive immunity against IgG immune complexes and is thus involved in the defense against infectious diseases and anti-tumor immunity. Therapeutic FcRn antagonists inhibit the recycling of IgG molecules and lead to a reduction in IgG serum levels. In the context of pregnancy, therapeutic FcRn antagonists inhibit transplacental IgG transport. This review is intended to present the status of the potential use of FcRn antagonists in immunohematological diseases caused by autoantibodies and in diseases of the fetus and newborn caused by maternal alloantibodies.

Harvard Citation style: Wienzek-Lischka, S. and Bein, G. (2024) The Neonatal Fc Receptor: Biological Basis and Potential of Therapeutic Blockade in the Treatment of Immunohematological Diseases, Transfusionsmedizin, 14(02), pp. 73-81. https://doi.org/10.1055/a-2138-6082

APA Citation style: Wienzek-Lischka, S., & Bein, G. (2024). The Neonatal Fc Receptor: Biological Basis and Potential of Therapeutic Blockade in the Treatment of Immunohematological Diseases. Transfusionsmedizin. 14(02), 73-81. https://doi.org/10.1055/a-2138-6082